1. Italy Stocks

  2. •

    Electronic technology

  3. •

    Electronic equipment/Instruments
GVS S.p.A

GVS S.p.A

5.19
EUR
+0.10
(+1.96%)
0.22EPS
19.61P/E
798.58MMarket Cap
Nov 11Next Earn
GVS S.p.A
GETTEX:4YQ
(Gettex)

Recent

price

5.19

P/E

ratio

19.61

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
1.65
2.09
2.27
2.64
1.94
2.22
2.49
2.44
2.3
2.26
Revenue per Share
0.06
0.23
0.33
0.57
0.39
0.14
0.08
0.19
0.1
0.22
Basic EPS, GAAP
0.11
0.32
0.42
0.6
0.18
0.31
0.43
0.34
0.06
0.29
Free Cash Flow per Basic Share
0.09
0.05
0.08
0.01
0.13
- -
- -
- -
- -
- -
Dividend per Share
0.33
0.41
0.54
1.39
1.69
1.88
1.91
2.39
2.34
2.4
Book Value per Share
-0.25
-0.17
-0.03
0.87
0.39
-0.96
-0.79
-0.12
0.02
0.06
Tangible Book Value per Share
100
100
100
138
175
175
171
176
184
188
Basic Weighted Avg Shares
165
209
227
363
338
388
425
429
425
424
Sales/Revenue/Turnover
12.33
16.39
19.79
32.84
23.94
7.94
11.75
13.67
13.91
14.37
Operating Margin (%)
13
18
16
19
24
38
44
44
45
46
Depreciation Expense
6
23
33
78
68
24
14
33
18
41
Net Income, GAAP
27.46
28.54
24.23
26.26
24.68
30.34
25.53
22.32
28.62
27.44
Effective Tax Rate (%)
3.66
11.04
14.55
21.49
19.99
6.22
3.21
7.79
4.34
9.62
Profit Margin (%)
65
62
66
153
178
-197
142
123
42
101
Working Capital
168
147
125
75
187
68
314
260
191
248
LT Debt
58
71
94
243
295
328
334
451
437
451
Total Equity
- -
9.65
13.54
28.53
13.67
2.89
4.4
5.57
5.31
5.5
Return on Invested Capital (%)
- -
10.61
14.33
26.91
15.7
4.35
3.66
6.28
3.43
6.33
Return on Capital (%)
- -
35.78
40.04
46.34
25.13
7.74
4.12
8.5
4.15
9.28
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
120
9
80
LT Borrowings
178
- -
234
LT Finance Leases
13
13
14
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
187
187
187
Market Capitalization
724
668
799

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
249
292
287
Cash, Cash Equivalents & STI
81
105
96
Accounts Receivable, Net
51
65
65
Inventories
90
99
106
Total Current Liabilities
206
162
186
Payables & Accruals
- -
- -
- -
ST Debt
120
9
80
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
13.3%
-3.11%
Free Cash Flow
- -
-11.58%
-81.15%
Net Income, GAAP
- -
-4.28%
-44.77%
Sales/Revenue/Turnover
- -
3.45%
-0.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
104
111
107
107
429
2025
107
108
100
109
425
2026
105
110
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.05
- -
0.08
0.19
2025
0.01
- -
0.04
0.05
0.1
2026
0.06
0.06
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Advantest Corp. (TSE:6857)
Unusual Machines, Inc. (AMEX:UMAC)
FuelCell Energy, Inc. (NASDAQ:FCEL)
Lasertec Corp. (TSE:6920)
Hitachi Energy India Limited (NSE:POWERINDIA)
Keysight Technologies Inc. (NYSE:KEYS)
Business
GVS S.p.A. (GVS.MI) manufactures and sells filtration and protection solutions for healthcare, life sciences, industrial, energy, and mobility applications. The company offers advanced filtration products including sterile venting filters, liquid filters, hydrophobic and hydrophilic membranes, gas filters, and protective masks; respiratory protection devices such as FFP2/FFP3 masks and powered air-purifying respirators; and engineered components like sealing solutions and purification systems. GVS operates globally across Europe, North America, Asia, and other regions, serving pharmaceutical, medical device, automotive, and industrial customers. Founded in 1979 and headquartered in Zola Predosa, Bologna, Italy, the company maintains production facilities in Italy, the United States, China, and elsewhere, with a focus on high-performance materials and cleanroom manufacturing. In recent developments, GVS completed the acquisition of Entegris' filtration business in late 2023, significantly expanding its healthcare and semiconductor filtration portfolio; launched new sterile filtration lines for biologics and single-use systems in 2024; and formed strategic partnerships for respiratory protection supply amid ongoing global health demands, alongside investments in U.S. manufacturing capacity to support North American growth.